[F:1][C:2]1[CH:3]=[C:4]([NH:18][C:19]2[CH:24]=[C:23]([CH:25]3[CH2:30][CH2:29][CH2:28][NH:27][CH2:26]3)[N:22]=[C:21]([NH2:31])[N:20]=2)[CH:5]=[CH:6][C:7]=1[O:8][C:9]1[CH:14]=[CH:13][N:12]=[C:11]2[NH:15][CH:16]=[CH:17][C:10]=12.Br[CH:33]([CH3:35])[CH3:34].C(=O)([O-])[O-].[K+].[K+]>CN(C=O)C>[F:1][C:2]1[CH:3]=[C:4]([NH:18][C:19]2[CH:24]=[C:23]([CH:25]3[CH2:30][CH2:29][CH2:28][N:27]([CH:33]([CH3:35])[CH3:34])[CH2:26]3)[N:22]=[C:21]([NH2:31])[N:20]=2)[CH:5]=[CH:6][C:7]=1[O:8][C:9]1[CH:14]=[CH:13][N:12]=[C:11]2[NH:15][CH:16]=[CH:17][C:10]=1250 mg (0.119 mmol) of N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-piperidin-3-ylpyrimidine-2,4-diamine (from example 134) are dissolved in DMF. 0.013 ml (0.143 mmol) of 2-bromopropane and 49 mg (0.358 mmol) of potassium carbonate are added, and the mixture is stirred at room temperature for 18 hours. The suspension is filtered off with suction and the filtrate is purified by preparative HPLC.